Literature DB >> 11854228

Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria.

Edwin A M Lee1, Dupeh R Palmer, Katie L Flanagan, William H H Reece, Kennedy Odhiambo, Kevin Marsh, Margaret Pinder, Michael B Gravenor, Wendy A Keitel, Kent E Kester, Carter Diggs, David Kaslow, V Apostolopoulos, W Ripley Ballou, Adrian V S Hill, Urszula Krzych, Magdalena Plebanski.   

Abstract

Plasmodium falciparum malaria is a major cause of death in the tropics. The 19-kDa subunit of P. falciparum merozoite surface protein 1 (MSP-1(19)), a major blood stage vaccine candidate, is the target of cellular and humoral immune responses in animals and humans. In this phase I trial of MSP-1(19), immunization of nonexposed human volunteers with either of the two allelic forms of recombinant MSP-1(19) induced high levels of antigen-specific Th1 (gamma interferon) and Th2 (interleukin 4 [IL-4] and IL-10) type lymphokines. The adjustment of the antigen dose and number of immunizations regulated the level of specificity of immune responses and Th1/Th2 bias of responses induced by vaccination. Novel conserved and allelic T-cell epitopes which induced cross-strain immune responses were identified. Importantly, responses to many of these novel epitopes were also present in adults exposed to malaria, both in east (Kenya) and west Africa (The Gambia). These data suggest that epitope-specific naturally acquired MSP-1(19) immune responses in endemic populations can be boosted by vaccination.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11854228      PMCID: PMC127736          DOI: 10.1128/IAI.70.3.1417-1421.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Reduction of disulfide bonds within lysosomes is a key step in antigen processing.

Authors:  D S Collins; E R Unanue; C V Harding
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

Review 2.  Dominance and crypticity of T cell antigenic determinants.

Authors:  E E Sercarz; P V Lehmann; A Ametani; G Benichou; A Miller; K Moudgil
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

3.  Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity.

Authors:  F al-Yaman; B Genton; K J Kramer; S P Chang; G S Hui; M Baisor; M P Alpers
Journal:  Am J Trop Med Hyg       Date:  1996-05       Impact factor: 2.345

Review 4.  Immune evasion in malaria: altered peptide ligands of the circumsporozoite protein.

Authors:  M Plebanski; E A Lee; A V Hill
Journal:  Parasitology       Date:  1997       Impact factor: 3.234

Review 5.  The immunogenetics of human infectious diseases.

Authors:  A V Hill
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

6.  Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling.

Authors:  J M Brewer; M Conacher; C A Hunter; M Mohrs; F Brombacher; J Alexander
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

7.  Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children.

Authors:  A J Luty; B Lell; R Schmidt-Ott; L G Lehman; D Luckner; B Greve; P Matousek; K Herbich; D Schmid; F Migot-Nabias; P Deloron; R S Nussenzweig; P G Kremsner
Journal:  J Infect Dis       Date:  1999-04       Impact factor: 5.226

8.  Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity.

Authors:  E M Riley; S J Allen; J G Wheeler; M J Blackman; S Bennett; B Takacs; H J Schönfeld; A A Holder; B M Greenwood
Journal:  Parasite Immunol       Date:  1992-05       Impact factor: 2.280

9.  Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages.

Authors:  H Bouharoun-Tayoun; C Oeuvray; F Lunel; P Druilhe
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

10.  A longitudinal study of naturally acquired cellular and humoral immune responses to a merozoite surface protein (MSP1) of Plasmodium falciparum in an area of seasonal malaria transmission.

Authors:  E M Riley; S Morris-Jones; M J Blackman; B M Greenwood; A A Holder
Journal:  Parasite Immunol       Date:  1993-09       Impact factor: 2.280

View more
  16 in total

Review 1.  Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations.

Authors:  Magdalena Plebanski; Owen Proudfoot; Dodie Pouniotis; Ross L Coppel; Vasso Apostolopoulos; Graham Flannery
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 2.  Building better T-cell-inducing malaria vaccines.

Authors:  Stephen M Todryk; Michael Walther
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

3.  Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum.

Authors:  Asma Abdullah Nurul; Mohd Nor Norazmi
Journal:  Parasitol Res       Date:  2010-11-06       Impact factor: 2.289

4.  Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide.

Authors:  Eliada Lazoura; Jodie Lodding; William Farrugia; Paul A Ramsland; James Stevens; Ian A Wilson; Geoffrey A Pietersz; Vasso Apostolopoulos
Journal:  Immunology       Date:  2006-11       Impact factor: 7.397

5.  An engineered Plasmodium falciparum C-terminal 19-kilodalton merozoite surface protein 1 vaccine candidate induces high levels of interferon-gamma production associated with cellular immune responses to specific peptide sequences in Gambian adults naturally exposed to malaria.

Authors:  C Bisseye; L M Yindom; J Simporé; W D Morgan; A A Holder; J Ismaili
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

6.  Differential cellular recognition of antigens during acute Plasmodium falciparum and Plasmodium vivax malaria.

Authors:  Ervi Salwati; Gabriela Minigo; Tonia Woodberry; Kim A Piera; Harini D de Silva; Enny Kenangalem; Emiliana Tjitra; Ross L Coppel; Ric N Price; Nicholas M Anstey; Magdalena Plebanski
Journal:  J Infect Dis       Date:  2011-04-15       Impact factor: 5.226

7.  Mannan-mediated gene delivery for cancer immunotherapy.

Authors:  Choon K Tang; Jodie Lodding; Gabriela Minigo; Dodie S Pouniotis; Magdalena Plebanski; Anja Scholzen; Ian F C McKenzie; Geoffrey A Pietersz; Vasso Apostolopoulos
Journal:  Immunology       Date:  2007-03       Impact factor: 7.397

8.  Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli.

Authors:  Suraksha Sachdeva; Gul Ahmad; Pawan Malhotra; Paushali Mukherjee; V S Chauhan
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

9.  Immune responses of mice with different genetic backgrounds to improved multiepitope, multitarget malaria vaccine candidate antigen FALVAC-1A.

Authors:  S A Kaba; A Price; Z Zhou; V Sundaram; P Schnake; I F Goldman; A A Lal; V Udhayakumar; C W Todd
Journal:  Clin Vaccine Immunol       Date:  2008-09-10

10.  A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria.

Authors:  Stephen A Kaba; Clara Brando; Qin Guo; Christian Mittelholzer; Senthilkumar Raman; David Tropel; Ueli Aebi; Peter Burkhard; David E Lanar
Journal:  J Immunol       Date:  2009-11-13       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.